Beneficial effects of mangiferin on hyperlipidemia in high-fat-fed hamsters

Mol Nutr Food Res. 2011 Dec;55(12):1809-18. doi: 10.1002/mnfr.201100392. Epub 2011 Oct 31.

Abstract

Scope: Mangiferin, a natural polyphenol, has been shown to have hypolipidemic effect in rat and mouse. However, the mechanism of action is not well understood. This study was conducted to determine the effect and mechanism of action of mangiferin on hyperlipidemia induced in hamsters by a high-fat diet.

Methods and results: Forty male hamsters were randomly assigned to normal control, high-fat control, and high fat with mangiferin (50 and 150 mg/kg BW) groups. Mangiferin treatment significantly decreased final body weight, liver weight and visceral fat-pad weight, serum triglyceride (TG) and total free fatty acid (FFA) concentrations, hepatic TG levels and hepatic and muscle total FFA contents. Mangiferin upregulated mRNA expression of peroxisome proliferator-activated receptor-α (PPAR-α), fatty acid translocase (CD36) and carnitine palmitoyltransferase 1 (CPT-1), but downregulated mRNA expression of sterol regulatory element-binding protein 1c (SREBP-1c), acetyl CoA carboxylase (ACC), acyl-CoA:diacylglycerol acyltransferase 2 (DGAT-2) and microsomal triglyceride transfer protein (MTP) in liver. Mangiferin also stimulated mRNA expression of PPAR-α, CD36, CPT-1 and lipoprotein lipase (LPL) in muscle.

Conclusions: The results suggest that mangiferin may ameliorate hypertriglyceridemia partly by modulating the expression levels of genes involved in lipid oxidation and lipogenesis.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acetyl-CoA Carboxylase / drug effects
  • Acetyl-CoA Carboxylase / genetics
  • Acetyl-CoA Carboxylase / metabolism
  • Adipose Tissue / drug effects
  • Animals
  • Body Weight / drug effects
  • CD36 Antigens / drug effects
  • CD36 Antigens / genetics
  • CD36 Antigens / metabolism
  • Carnitine O-Palmitoyltransferase / drug effects
  • Carnitine O-Palmitoyltransferase / genetics
  • Carnitine O-Palmitoyltransferase / metabolism
  • Carrier Proteins / drug effects
  • Carrier Proteins / genetics
  • Carrier Proteins / metabolism
  • Cricetinae
  • Diacylglycerol O-Acyltransferase / drug effects
  • Diacylglycerol O-Acyltransferase / genetics
  • Diacylglycerol O-Acyltransferase / metabolism
  • Diet, High-Fat*
  • Dietary Fats / administration & dosage*
  • Down-Regulation
  • Fatty Acids, Nonesterified / blood
  • Hyperlipidemias / drug therapy*
  • Hypertriglyceridemia / drug therapy
  • Hypolipidemic Agents / pharmacology*
  • Lipid Metabolism / drug effects
  • Lipid Metabolism / genetics
  • Lipogenesis / drug effects
  • Lipogenesis / genetics
  • Lipoprotein Lipase / drug effects
  • Lipoprotein Lipase / genetics
  • Lipoprotein Lipase / metabolism
  • Liver / drug effects
  • Liver / metabolism
  • Male
  • Organ Size / drug effects
  • PPAR alpha / drug effects
  • PPAR alpha / genetics
  • PPAR alpha / metabolism
  • RNA, Messenger / genetics
  • RNA, Messenger / metabolism
  • Sterol Regulatory Element Binding Protein 1 / drug effects
  • Sterol Regulatory Element Binding Protein 1 / genetics
  • Sterol Regulatory Element Binding Protein 1 / metabolism
  • Triglycerides / blood
  • Up-Regulation
  • Xanthones / pharmacology*

Substances

  • CD36 Antigens
  • Carrier Proteins
  • Dietary Fats
  • Fatty Acids, Nonesterified
  • Hypolipidemic Agents
  • PPAR alpha
  • RNA, Messenger
  • Sterol Regulatory Element Binding Protein 1
  • Triglycerides
  • Xanthones
  • microsomal triglyceride transfer protein
  • mangiferin
  • Diacylglycerol O-Acyltransferase
  • Carnitine O-Palmitoyltransferase
  • Lipoprotein Lipase
  • Acetyl-CoA Carboxylase